Thermo Fisher Scientific will more than double its viral vector development and manufacturing capacity by building a USD180 million US commercial production facility in Plainville, Massachusetts, the contract development and manufacturing organisation (CDMO) announced on Monday.
The company said the project will support increasing demand for the development and manufacture of treatments and vaccines in the fast-growing cell and gene therapy space.
Construction of the 290,000-square-foot facility – which will complement Thermo Fisher’s existing US sites at Lexington, Cambridge and Alachua -- is expected to be completed in 2022.
Michel Lagarde, executive vice president of Thermo Fisher said the expansion would provide customers with an uninterrupted pathway from development through commercialization.
“Between Plainville and our other expanded sites in the US, we're increasing viral vector production to accelerate cell and gene therapy innovation,” he added.
The Plainville site will house laboratory and production suites adjacent to warehousing and office space. An onsite engineering laboratory will develop turnkey production platforms in readiness for the transition to commercial-scale operations.
Thermo Fisher rapidly expanded its viral vector development and manufacturing capabilities through its acquisition of Brammer Bio last year, opening a new site in Lexington and expanding the sites in Cambridge and Alachua.